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Abstract
Background: Dermatomyositis is an inflammatory muscle disease caused by immune-mediated muscle injury, and
central core disease (CCD) is a congenital myopathy associated with disturbed intracellular calcium homeostasis
and excitation-contraction coupling. To date, CCD has not been reported to have autoantibodies or coexist with
inflammatory myopathy.
Case presentation: Here, we described the case of a 25-year-old woman who had progressive proximal muscle
weakness, myalgia, pruritic macular rash, skin ulcers, and calcinosis. Dermatomyositis was initially suspected based
on the clinical symptoms accompanied by elevated muscle enzyme levels, electromyography abnormalities, and a
positive antinuclear antibody test. However, the patient’s muscle biopsy revealed the characteristic findings of both
dermatomyositis and CCD, suggesting that dermatomyositis occurred in this patient with previously asymptomatic
CCD. The patient did not have any pathogenic gene mutations associated with congenital myopathy, including
RYR1 and SEPN1 in targeted next-generation sequencing. She received high-dose glucocorticoid therapy and
azathioprine with a significant improvement in muscle strength.
Conclusions: We present a case of rare coexistence of dermatomyositis and CCD. Clinicians should be aware that
patients with CCD may have inflammatory myopathy that responds well to immunosuppressive therapy.
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Background
Dermatomyositis and central core disease (CCD) are
well-recognized, distinct muscle diseases. Dermatomyositis
is an autoimmune inflammatory myopathy associated with
progressive proximal muscle weakness, a characteristic
rash and extramuscular manifestations [1]. CCD is a
congenital myopathy characterized by the early onset of
hypotonia, predominantly proximal muscle weakness and
histopathological features of focally reduced oxidative
enzyme activity seen as the central core. Congenital dis-
location of the hips and scoliosis and foot deformities are
common in CCD [2]. CCD is mainly due to dominant
mutations in the ryanodine receptor 1 (RYR1) gene, which
encodes channel proteins involved in skeletal muscle
calcium homeostasis and excitation-contraction coupling
(ECC) [3]. The severity of muscle weakness in patients with
CCD due to dominant RYR1 mutation is usually mild;
most patients with CCD achieve independent ambulation
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with slow progression, and are clinically asymptomatic
even in about 40% of patients with histological signs of
disease [4, 5].
There seems to be little relationship between inflam-
matory myopathy and genetic muscle diseases. However,
there have been descriptions of patients with muscular
dystrophy and myositis-specific autoantibodies [6]. The
presence of autoantibodies may exacerbate muscle in-
flammation due to the high levels of autoantigens
expressed by regenerating muscle cells, leading to over-
lapping inflammatory myopathy. To date, congenital
myopathy has not been reported to have autoantibodies
or coexist with inflammatory myopathy.
Here, we report a rare case of dermatomyositis
coexisting with CCD presenting as severe progressive
proximal muscle weakness and a skin rash with ulcera-
tions and calcinosis.
Case presentation
A previously healthy 25-year-old Korean woman had a
two-month history of progressive proximal muscle
weakness. She had myalgia, fever, severe alopecia and a
pruritic macular rash over her face, hand dorsum, upper
anterior chest and upper back. She had difficulty in sit-
ting up and could only move around using a wheelchair.
She had no hypotonia, feeding difficulty, dysarthria,
motor developmental delay, or orthopaedic abnormal-
ities in infancy or early childhood. Her family history
was unremarkable.
On physical examination, her vital signs were stable,
and her body mass index was 21.8 kg/m2 (height 156 cm,
weight 53 kg). Her bilateral muscle strength was grade
4/5 at neck flexion, 4/5 at shoulder abduction, 4/5 in
wrist flexion, 4/5 in hand grip, 2/5 in the proximal hips,
and 4/5 in ankle dorsiflexion. She had normal reflexes of
the biceps brachii, patella, and ankle. Facial erythema in-
volving the nasolabial folds and an erythematous rash on
the upper back and anterior chest wall compatible with
V-neck sign and shawl sign were observed. Skin ulcers
were seen on the hand knuckles, right elbow and lateral
aspect of the right thigh (Fig. 1). She had widespread,
palpable soft tissue thickening of the bilateral thigh and
upper arm with tenderness, which turned out to be
calcification. The laboratory results were as follows:
white blood cell count, 6440/mm3 with lymphopenia
(lymphocyte 322/mm3); haemoglobin, 9.1 g/dL; platelet,
148,000/mm3; erythrocyte sedimentation rate (ESR), 72
mm/hr.; C-reactive protein (CRP), 0.44 mg/dL; aspartate
aminotransferase (AST), 95 (1–40) IU/L; alanine amino-
transferase (ALT), 30 (1–40) IU/L; creatine kinase (CK),
128 (20–270) IU/L; lactate dehydrogenase (LDH), 553
(100–225) g/dL; myoglobin, 47.1 (0–106) ng/mL; aldol-
ase, 10.8 (0–7.6) U/L; C3, 83 (83–193) mg/dL; and C4,
19 (15–57) mg/dL. The antinuclear antibody test was
positive and showed a homogeneous pattern at a 1:160
dilution, but the anti-dsDNA, anti-Sm, anti-Ro, anti-La,
anti-Scl-70, anti-centromere, anti-U1 ribonucleoprotein,
anti-phospholipid, and anti-Jo-1 antibody tests were all
negative. Magnetic resonance imaging (MRI) of the
thigh showed symmetric diffuse muscle signal changes
with an enhanced T2 signal and diffuse patchy contrast
enhancement involving both the anterior and posterior
compartments of the thigh (Fig. 2). Her radiographs of
shoulders and pelvis showed extensive, plaque-like soft
tissue calcification of both hips, thighs and upper arms.
Electromyography (EMG) showed fibrillations, positive
sharp waves (PSWs), increased amplitudes of motor unit
action potential (MUAP) and reduced interference
pattern in the biceps. In the EMG of the tibialis and
gastrocnemius muscles, fibrillations, PSWs, small and
polyphasic MUAPs, and reduced interference pattern
were identified. In contrast, the nerve conduction study
revealed normal responses. A muscle biopsy of the right
vastus lateralis demonstrated many degenerating and
regenerating muscle fibers and perifascicular atrophy
with moderate infiltration of inflammatory cells in the
endomysial and perivascular areas, consistent with
dermatomyositis. However, enzyme histochemical analysis
showed centrally placed cores in the type I myofibers with
nicotinamide adenine dinucleotide dehydrogenase (NADH)
Fig. 1 Skin ulcerations on A the elbow and B thigh
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and succinate dehydrogenase (SDH) staining, suggesting
CCD (Fig. 3a). Electron microscopy showed both tubulore-
ticular bodies in the endothelial cells and disorganized
myofilaments with scattered short Z-bands and structured
central cores in the muscle fibers, findings that suggested a
diagnosis of CCD with superimposed dermatomyositis
(Fig. 3c and d). Computed tomography of the chest
and abdomen showed no evidence of interstitial lung
disease or malignancy. The echocardiography was
normal. The patient had no pathogenic mutations in
the genes associated with congenital myopathy, including
RYR1, SEPN1, ACTA1, AGRN, BIN1, CFL2, CHAT, CHRN
A1, CHRNB1, CHRND, CHRNE, COLQ, DNM2, DOK2,
GFPT1, IGHMBP2, KBTBD13, KLHL40, LAMB2, MTM1,
MUSK, MYH7, RAPSN, SLC5A7, SMN1, TNNT1, TPM2,
TPM3 and TTN, in hybridization capture-based next-
generation sequencing. However, she had a heterozygous
mutation in the NEB gene of c.8318G >A (p.Arg2773Gln),
which is considered a variant of uncertain significance.
Parental genetic testing was negative.
The patient received intravenous methylprednisolone
at 100 mg daily for 3 days, followed by oral prednisolone
at 25 mg twice a day and azathioprine at 50 mg daily.
Additionally, she started regular physiotherapy and
rehabilitation to maintain mobility. One month later, the
patient had a significant improvement in muscle
strength with a decrease in muscle enzyme levels (Fig. 4).
The muscle strength for hip flexion improved to grade
4/5 after 1 month of treatment and to grade 5/5 (nor-
mal) after 3 months of treatment. The patient did not
complain of respiratory symptoms and had no abnormal
findings on chest radiographs after 1 year of follow-up.
Currently, the patient is able to walk on her own, and is
taking 7.5 mg/day of prednisolone and 100 mg/day of
azathioprine.
Discussion
Dermatomyositis is an immune-mediated inflammatory
muscle disease characterized by proximal muscle weak-
ness. In contrast, CCD shows the disruption of intracel-
lular muscle calcium homeostasis and ECC by genetic
mutations, and is associated with typically proximal
muscle weakness. We described a patient with severe,
debilitating proximal muscle weakness, elevated muscle
enzyme levels, myopathic EMG abnormalities, skin rash,
and calcinosis who was clinically diagnosed with derm-
atomyositis. However, her muscle biopsy revealed the
characteristic findings of both dermatomyositis and
CCD, suggesting that dermatomyositis occurred in this
CCD patient who had no previous symptoms. The coexist-
ence of dermatomyositis and CCD may be a coincidence,
but it may also suggest a link between autoimmunity and
genetic muscle disease that affects intracellular calcium
homeostasis.
The congenital myopathies are a group of early-onset,
non-dystrophic genetic neuromuscular diseases with
Fig. 2 Magnetic resonance imaging of the thigh. Coronal images show A increased T2 signal intensity and B normal T1 signal intensity in the
pelvis and proximal thigh. C Axial T2-weighted and D gadolinium-enhanced T1-weighted image shows symmetric diffuse muscle edema and
inflammation with relative preservation in the left anterior compartment of the thigh
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characteristic muscle biopsy findings, consisting of CCD,
multi-minicore disease (MmD), centronuclear myopathy
and nemaline myopathy [2]. Congenital myopathies have
been attributed to mutations in genes encoding proteins
implicated in skeletal muscle calcium homeostasis, ECC,
thin–thick filament assembly, and their interactions [2].
For a muscle contraction to occur, calcium release from
the sarcoplasmic reticulum (SR) to the sarcoplasm leads
to sarcomere shortening through interactions between
the thin and thick filaments driven by adenosine triphos-
phate (ATP) [7]. This ECC is terminated by calcium
reuptake by the SR. Therefore, continuous calcium leak
to the sarcoplasm and disturbed ECC causes muscle
weakness to develop in congenital myopathies, especially
CCD. Histologically, CCD is characterized by centrally
located, well-demarcated cores of diminished or absent
oxidative enzyme activity in the muscle fibers. Type I
fiber predominance and atrophy are common in CCD
[8]. CK levels may be normal or mildly elevated. Select-
ive muscle involvement with increased T1 signal seen on
muscle MRI depends on the subset of congenital myop-
athy, which can also be distinguished from inflammatory
myopathy [9].
CCD is closely associated with dominant RYR1 muta-
tions, implying that the typical central cores on muscle
biopsy are highly suggestive of RYR1 defect [2]. Previ-
ously, RYR1 mutations was reported to be responsible
for 47–67% of patients with CCD, suggesting that the
disease is genetically heterogeneous [10–12]. However,
the mutation screening performed in these studies was
limited to the three hot spots of the RYR1 gene, espe-
cially the C-terminal region most relevant to CCD. In
contrast, a previous study covering the full coding
regions of the RYR1 gene in a cohort of Japanese CCD
patients showed that RYR1 mutations occur in 93% of
CCD patients [12]. Of note, functional studies are
needed when mutations are detected in the RYR1 and
NEB genes which are associated with congenital myop-
athies, as variants of uncertain significance are common
in these genes due to their large size [13]. In addition,
mutations in the RYR1-binding proteins, FKBP12 and
CACNA1S, identified as directly participating in ECC,
may also contribute to the RYR1 channel dysfunction
[14]. Mutations have been identified in CACNA1S in pa-
tients with malignant hyperthermia and primary periodic
paralysis [12, 15]. Thus, RYR1-binding proteins may also
need to be studied in more detail in patients with CCD.
Targeted next-generation sequencing did not detect
any genetic mutations related to congenital myopathy,
including RYR1, in our patient. However, the typical
central cores were clearly revealed by NADH and SDH
staining of a majority of muscle fibers in the patient. In
addition, ultrastructually, disarray of the myofilaments
with scattered short Z-bands and structured central
Fig. 3 Histological findings in a muscle biopsy specimen obtained from the vastus lateralis. A NADH-tetrazolium reductase stain shows irregularly
outlined central cores in the type I myofibers (bar: 200 μm). B ATPase pH 4.3 shows pale central cores in the type I myofibers (bar: 200 μm).
Electron microscopy (adenyl acetate and lead citrate stain) shows C a structured central core composed of randomly scattered short Z-bands and
fine filaments (arrow) (bar: 5 μm), and D two tubuloreticular bodies (arrows) in the endothelial cells (bar: 500 nm)
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cores was observed, which is highly suggestive of CCD.
Inclusion body myositis can show mitochondrial abnor-
malities such as cytochrome c oxidase (COX) deficiency
in muscle fibers, but COX-negative/SDH-positive stain-
ing is seen throughout the muscle fibers rather than in
the central region [16]. Histological signs of deficiency
in oxidative enzyme activities in dermatomyositis and
polymyositis have not been shown in previous reports.
Patients with CCD without identifiable RYR1 mutations
may have mutations in unknown genes or RYR1
mutations may still exist in unexamined regions such as
promoter region, introns and casual copy number
variations.
Several muscular dystrophies, such as facioscapulo-
humeral dystrophy and limb-girdle muscular dystrophy,
show muscle regeneration and inflammatory cell infil-
trates in muscle fibers, similar to inflammatory myop-
athy [17]. Additionally, myositis-specific autoantibodies
such as anti-Jo-1 and anti-Mi2 were found in patients
with muscular dystrophy [6]. Based on these findings,
autoantigens may be expressed in the regenerating
muscle fibers of muscular dystrophy, triggering an
autoimmune process and overlapping with inflammatory
myopathy [18]. In contrast, congenital myopathies rarely
show muscle regeneration, and may lead to very low
levels of myositis autoantigen expression. Instead,
aberrant intracellular calcium homeostasis in congenital
myopathy may affect the immune system. For instance,
increased T cell receptor-mediated calcium influx in
lupus T cells contributes to T cell activation by inducing
the activation of calcineurin [19]. RYR1, a calcium-release
channel protein associated with CCD, is expressed prefer-
entially in skeletal muscle, but is also expressed in B cells
and dendritic cells. RYR1-mediated intracellular calcium
influx in B cells and dendritic cells may cause their
activation and the release of pro-inflammatory cytokines
[20–22]. Interestingly, dermatomyositis is characterized by
abnormal humoral immunity related to B cell activation
producing autoantibodies. Previous studies have reported
rare cases of muscular dystrophy coexisting with autoanti-
bodies. However, to the best of our knowledge, this is the
first report of inflammatory myopathy coexisting with
congenital myopathy and the first report of autoantibodies
found in the patient with congenital myopathy. Further
Fig. 4 Changes in serum levels of skeletal muscle enzymes and daily doses of glucocorticoid during the follow-up period. AST, aspartate
aminotransferase, CK, creatine kinase, LDH, lactate dehydrogenase, PD, prednisolone, mPd, methylprednisolone
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studies on autoantibodies in CCD patients may be needed
when dermatomyositis or other autoimmune disease is
suspected in patients with CCD.
The management of congenital myopathies is mainly
supportive [23], whereas inflammatory myopathies
respond well to treatment with glucocorticoid and im-
munosuppressive agents. Immunosuppressive therapy
was also effective in improving muscle strength in the
present case with dermatomyositis coexisting with CCD.
Therefore, inflammatory myopathy should be suspected
in a patient with congenital myopathy if he or she pre-
sents with a sudden deterioration in muscle strength,
particularly along with extramuscular symptoms or the
presence of autoantibodies. We suggest that a muscle
biopsy or MRI should be performed to evaluate for over-
lapping inflammatory myopathy.
In summary, we reported a rare case of the coexistence
of dermatomyositis and CCD. Clinicians should be
aware that patients with CCD could have inflammatory
myopathy, which responds well to immunosuppressive
therapy. Testing for autoantibodies, and muscle MRI or
muscle biopsy may help distinguish between inflamma-
tory myopathy and underlying genetic muscle diseases.
Further research may be needed to decipher the associ-
ation between autoimmunity and congenital myopathy-
associated intracellular calcium homeostasis.
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